We are live on ! Find out more
EHI

Eagle Health Investments Portfolio holdings

AUM $603M
1-Year Est. Return 111.06%
This Fund
S&P 500
This Quarter Est. Return
+37.14%
1 Year Est. Return
+111.06%
3 Year Est. Return
+240.87%
5 Year Est. Return
+290.92%
10 Year Est. Return
AUM
$603M
AUM Growth
+$31.5M
Cap. Flow
-$94.5M
Cap. Flow %
-15.67%
Top 10 Hldgs %
66.11%
Holding
33
New
5
Increased
10
Reduced
4
Closed
6

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
2 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IMCR icon
26
Immunocore
IMCR
$1.73B
$1.47M 0.24%
46,300
PCSC
27
DELISTED
Perceptive Capital Solutions
PCSC
$410K 0.07%
37,686
BBIO icon
28
BridgeBio Pharma
BBIO
$16.6B
-267,031
Closed -$19.8M
CNTA
29
DELISTED
Centessa Pharmaceuticals
CNTA
-214,291
Closed -$8.51M
PRCT icon
30
CALL
Procept Biorobotics
PRCT
$1.24B
-90,000
Closed -$2.25M
PRCT icon
31
Procept Biorobotics
PRCT
$1.24B
-483,815
Closed -$12.1M
TERN
32
DELISTED
Terns Pharmaceuticals
TERN
-412,497
Closed -$21.7M
XBI icon
33
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
-730,000
Closed -$93.2M

Similar funds

Eagle Health Investments's Q2 2026 Portfolio in Review

As of Q2 2026, Eagle Health Investments held 33 positions worth $603M, up 5.5% from $572M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Eagle Health Investments withdrew a net $94.5M in Q2 2026, closing 6 positions and reducing 4 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $21.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 83% a quarter earlier, followed by Financials.

Against the trend, Eagle Health Investments opened a new position in Ionis Pharmaceuticals worth $15.4M.

  • Eagle Health Investments's largest Q2 2026 buy was Ionis Pharmaceuticals: 194,577 shares worth $15.4M.
  • Eagle Health Investments added most to Insmed in Q2 2026, an estimated $19.4M increase.
  • Eagle Health Investments's biggest Q2 2026 reduction was Natera, cutting an estimated $22.6M.
  • Eagle Health Investments fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $21.7M.
  • Eagle Health Investments's ten largest holdings make up 66% of its $603M portfolio in Q2 2026.
  • Eagle Health Investments opened 5 new positions and closed 6 in Q2 2026.
  • Eagle Health Investments's portfolio value rose 5.5% quarter-over-quarter to $603M.

Based on Eagle Health Investments's 13F filing for Q2 2026, filed 10 Aug 2026.